Fibrocell Science, Inc. Announces Second Quarter 2012 LAVIV Order Information

Fibrocell Science, Inc. Announces Second Quarter 2012 LAVIV Order Information

Fibrocell Science, Inc. (OTCBB: FCSC), announced today its LAVIV order information for the second quarter ended June 30, 2012.

During the second quarter of 2012, Fibrocell received orders for 387 biopsies, an increase of 104% as compared to 189 orders during the first quarter of 2012. During the second quarter of 2012, 85 new physicians placed orders for biopsies, an increase of 60% as compared to 53 new physicians during the first quarter of 2012. During the second quarter of 2012, 39 physicians placed repeat orders for biopsies, an increase of 200% as compared to 13 physicians during the first quarter of 2012. Since the launch of LAVIV in June 2011, Fibrocell has received 706 biopsy orders from 162 physicians.

David Pernock, Fibrocell Science Chairman and CEO, commented, “We are pleased with the strong demand for LAVIV, which is being driven by reorders and rapid growth in first-time ordering physicians. July and August are completely booked, and September is nearly 50% booked. To meet increasing demand, we have plans for expansion, and we are in discussions with proper regulatory agencies for approval to proceed with our plans.”

“We will continue to provide these updates to investors regarding our progress with LAVIV, as well as on further material developments through press releases and conference calls, when regulatory requirements permit,” concluded Mr. Pernock.

LAVIV was approved by the FDA on June 21, 2011 for the improvement of the appearance of moderate-to-severe nasolabial fold wrinkles in adults and is the first and only personalized cell therapy approved by the FDA for aesthetic use. LAVIVis now available in major metropolitan areas throughout the U.S., exclusively through board-certified dermatologists and plastic surgeons who have been trained by Fibrocell Science on the treatment process. A list of trained and certified physicians is available at and will be continually updated as new physicians are trained and begin offering LAVIV in their practice.

Fibrocell Science is conducting research to identify other potential uses of LAVIV and their proprietary fibroblast technology. There is no timeline regarding when Fibrocell Science will seek FDA regulatory approval for additional uses.

LAVIV is made especially for you from your own skin cells. Using someone else’s cells can cause a serious reaction. Prior to injection, confirm with your physician that your information on the LAVIV vial is correct. The most common side effects of LAVIV are at the injection-site, including redness, bruising, swelling, pain, bleeding, lumps, irritation, and itchiness. In clinical trials with LAVIV, most injection-site adverse reactions resolved within one week and most required no treatment. Your health care provider will help you to decide whether you are a candidate for LAVIV and may help you avoid some of the adverse reactions from LAVIV.

Before getting LAVIV, tell your healthcare provider if you have any medical problems including allergic reactions to any drugs or food, bleeding disorders or take blood-thinning medicines like aspirin, ibuprofen, or Coumadin® (warfarin sodium), keloids or excessive scarring, skin cancer or any malignancy, genetic disorders affecting your skin, immune problems or take medicines that affect your immune system, or any other illness or medical problem. The full Prescribing Information for LAVIV includes additional warnings about adverse reactions that occurred in less than 1% of patients following LAVIV treatment in clinical trials. Talk to your healthcare provider about these warnings. Please tell your healthcare provider if you are allergic to the antibiotics amphotericin or gentamicin, bovine materials (products made from cattle), or dimethyl sulfoxide(DMSO).

Do not use LAVIV if you have a skin infection on your face because LAVIV treatment can make the infection worse.

Please see the accompanying full prescribing information for LAVIV contraindications, warnings, precautions and adverse events or visit .

Fibrocell Science, Inc. (OTCBB:FCSC) is an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit .